HBM HOLDINGS-B (02142): Investigational New Drug Application for LET003 Accepted by the National Medical Products Administration
HBM HOLDINGS-B (02142) announced that the National Medical Products Administration (NMPA) of China has accepted the Investigational New Drug (IND) application for LET003, the Company's first next-generation monoclonal antibody targeting ACVR2A/2B developed using the Hu-mAtrIx AI platform, for the treatment of overweight or obesity. LET003 is a potential best-in-class next-generation monoclonal antibody targeting activin receptors ACVR2A and ACVR2B, which play a key role in regulating muscle-fat metabolic homeostasis.
HBM HOLDINGS-B (02142) announced that the National Medical Products Administration (NMPA) of China has accepted the Investigational New Drug (IND) application for LET003, the company's first next-generation monoclonal antibody targeting ACVR2A/2B developed using the Hu-mAtrIx AI platform, for the treatment of overweight or obesity. LET003 is a potential best-in-class next-generation monoclonal antibody targeting activin receptors ACVR2A and ACVR2B, which play a key role in regulating muscle-fat metabolic homeostasis.
LET003 is the company's first AI-enabled drug candidate, designed to act through dual-target blockade of ACVR2A and ACVR2B. Preclinical studies showed that LET003 has superior pharmacokinetic profiles compared with multiple competing molecules of the same class. When used in combination with semaglutide, LET003 can significantly enhance fat loss while effectively preserving lean body mass. In addition, LET003 achieved lean mass preservation effects comparable to high-dose bimagrumab at lower dose levels, highlighting its potential to become a best-in-class therapy in the field of overweight or obesity treatment.
Related Articles

HK Stock Market Move | CATHAY PAC AIR (00293) rises over 3%; October passenger traffic up 4% year-on-year; JP Morgan bullish on its market share and yield advantages.

HK Stock Market Move | IMPACT THERAP-B (07630) rose over 15% against the market trend as Senaparib received EU approval for first-line maintenance treatment of ovarian cancer in the all-comer population.

UBS: Cuts CHINA RES MIXC (01209) target price to HK$52, maintains "Buy" rating.
HK Stock Market Move | CATHAY PAC AIR (00293) rises over 3%; October passenger traffic up 4% year-on-year; JP Morgan bullish on its market share and yield advantages.

HK Stock Market Move | IMPACT THERAP-B (07630) rose over 15% against the market trend as Senaparib received EU approval for first-line maintenance treatment of ovarian cancer in the all-comer population.

UBS: Cuts CHINA RES MIXC (01209) target price to HK$52, maintains "Buy" rating.






